ROS1 | GenomeWeb

ROS1

Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.

Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.

The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.

In developing the recommendations, the expert panel attempted to keep up with the fast-moving advances in oncology.

Entrectinib is Ignyta's lead product that the biotech is investigating in patients with tumors characterized by TrkA, TrkB, TrkC, ROS1, and ALK markers.

This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.